Pancreatic ductal adenocarcinoma kills roughly 88% of patients within five years, and checkpoint inhibitors have done almost nothing for it — which makes a 52.4% objective response rate at the 2 mg/kg dose of spevatamig plus gemcitabine/nab-paclitaxel a number worth examining carefully. For context, the GnP backbone alone produced ORRs in the 23–31% range in the pivotal trials that established it as standard of care. A doubling of that signal, even in a non-randomized Phase 2 cohort, demands scrutiny rather than celebration.
The mechanism is the central argument here. Spevatamig is a CLDN18.2/CD47 bispecific that operates as an innate immunity enhancer — activating macrophages and dendritic cells rather than T cells. PDAC is immunologically cold precisely because its dense stromal architecture excludes T cells; innate immune activation sidesteps that barrier entirely. The 90.5% disease control rate and a median OS of 14.7 months in U.S. patients suggest the biology is doing something real. Critically, more than 90% of patients at this dose level had de novo metastatic disease, which aligns the population with Phase 3 historical controls and strengthens any future comparative inference.
There are legitimate design limitations to hold in mind. This is a single-arm study, not randomized. The 2 mg/kg cohort is the mature dataset; the 3 mg/kg cohort — which Phanes considers the Phase 3 candidate dose — is still accruing, with efficacy data expected in the second half of 2026. The PFS of 7.3 months at 2 mg/kg is modestly better than historical GnP data but not transformative on its own. Whether 3 mg/kg bends those curves meaningfully further is the open question. The tolerability profile, built on more than 190 patients dosed globally with no significant additive toxicity to GnP, at least clears the safety threshold needed to run a registrational trial.
The single number to watch when the 3 mg/kg data read out is median PFS. If it crosses 9 months with a comparable safety profile, the randomized Phase 3 design becomes not just feasible but urgent — and the CLDN18.2 target suddenly has a credible innate immune contender alongside the antibody-drug conjugate approaches already in late-stage development.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
